ACHE and early-onset autosomal dominant Alzheimer disease: Rivastigmine is noted for its dual inhibition of both AChE and butyrylcholinesterase (BChE), which is beneficial, given that butyrylcholinesterase activity tends to increase in the later stages of Alzheimer’s disease, while AChE activity decreases [8].